FOLH1 and posterior cortical atrophy: However, its utility in PCa diagnosis is not clear, and its use has been restricted to in vitro inhibition of PSMA. The second one is an unmodified RNA aptamer selected against the recombinant prostate-specific antigen (PSA) which was able to distinguish between the active and inactive forms of the enzyme40, but its diagnostic utility is questionable.